Overview

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tirzepatide